The effect of lipoprotein-a on thrombolytic therapy and spontaneous reperfusion in acute myocardial infarction. A comparative study

International Angiology

Volumn 21, Issue 4, 2002, Pages 384-389

  Dagdelen, Sinan ^a   Eren, N ^b   Akdemir, I ^b   Karabulut, H ^b   Ergelen, M ^a   Caglar, N ^b  

^a KOSUYOLU HEART AND RESEARCH HOSPITAL   (Turkey)

^b Acibadem Hospital   (Turkey)

Author keywords

Lipoprotein(a); Myocardial infarction; Thrombolytic therapy

Indexed keywords

ACETYLSALICYLIC ACID; FIBRINOLYTIC AGENT; HEPARIN; LIPOPROTEIN A; STREPTOKINASE; TISSUE PLASMINOGEN ACTIVATOR;

ACUTE HEART INFARCTION; ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; FIBRINOLYTIC THERAPY; HEART MUSCLE PERFUSION; HEART MUSCLE REPERFUSION; HUMAN; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STATISTICAL ANALYSIS; TREATMENT OUTCOME; VASCULAR PATENCY;

ADULT; AGED; CORONARY ANGIOGRAPHY; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; LIPOPROTEIN(A); MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION; OUTCOME ASSESSMENT (HEALTH CARE); STREPTOKINASE; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR; VASCULAR PATENCY;

EID: 0345700738     PISSN: 03929590     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. GISSI Study Group. Effectiveness of intravenous thrombolytic treatment in acut myocardial infarction. Lancet 1986;I:397-401.
2. ISIS 2 (Second International Study of Infarct Survival Colloborative Group). Randomised trial of intravenous streptokinase, oral aspirin, both or neither among 17187 cases of suspected myocardial infarction. Lancet 1988;II: 349-60.
3. Chesebro JH, Knatterud G, Roberts R, Borer J, Cohen LS, Dalen J et al. Thrombolysis in Myocardial Infarction (TIMI) Trial phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. Circulation 1987;76:142-54.
4. Van der Werf F, Arnold AER. For the European Cooperative Study Group for recombinant tissue plasminogen activator. Intravenous tissue plasminogen activator and the size of infarcts, left ventricular function and survival in acute myocardial infarction. BMJ 1988;297: 1364-79.
5. White HD, Norris RM, Brown MA, Takayama M, Maslowski A, Bass NM et al. Effect of intravenous streptokinase on left ventricular function and early survival after acute myocardial infarction. N Engl J Med 1987;317: 850-5.
6. AIMS Trial Study Group. Effect of intravenous APSAC on mortality after acute myocardial infarction: a preliminary report of a placebo-controlled clinical trial. Lancet 1988;1:545-9.
7. ISIS 3. A randomised comparison of streptokinase versus tissue plasminogen activator versus anistreplase and aspirin plus heparin versus aspirin alone among 41,299 cases of suspected acute myocardial infarction. ISIS-3 (Third International Study of Infarct Survival) Collaborative Group. Lancet 1992;339:753-70.
8. Durrington PN, Ishola M, Hunt L, Arrol S, Bhatnager D. Apolipoprotein(a), AI and B and parental history in men with early onset ischaemic heart disease. Lancet 1988;1: 1070-3.
9. Tokgözoǧlu SL, Ozmen F, Kabukçu M, Karanfil A, Aytemir K, Ozkuyumcu C et al. Does increased lipoprotein(a) impair the effectiveness of thrombolysis with streptokinase? Angiology 1995;46:727-31.
10. Kostner GM, Avogaro P, Cazzolata G, Marth E, Bittolo-Bon G, Quinci GB. Lipoprotein(a) and the risk for myocaardial infarction. Atherosclerosis 1981;38:51-61.
11. Dahlen GH, Guyton JR, Attar M, Farmer JA, Kautz JA, Gotto AM. Association of levels of lipoprotein(a), plasma lipids and other lipoproteins with coronary artery disease documanted by angiography. Circulation 1986;74: 758-65.
12. Uterman G. The mysteries of lipoprotein(a). Science 1989;246:904-10.
13. Cantin B, Gagnon F, Moorjani S, Despres JP, Lamarche B, Lupien PS et al. Is lipoprotein(a) an independent risk factor for ischemic heart disease in men? The Quebec Cardiovascular Study. J Am Coll Cardiol 1998;31:519-25.
14. Miles LA, Plow EF. Lp(a): an interpoler with the fibrinolytic system. Thromb Haemost 1990;63:331-5.
15. Bevvu AD, Durrington PN. Lipoprotein(a): structure properties and possible involvement in thrombogenesis and atherogenesis. Atherosclerosis 1990;85:1-14.
16. Gonzales-Gronow M, Edelberg JM, Pizzo SV. Further charecterization of the cellular plasminogen binding site. Evidence that plasminogen 2 and lipoprotein(a) compete for the same side. Biochemistry 1989;28:213-20.
17. Hodenberg E, Kreuzer J, Hautmann M, Nordt T, Kubler W, Bode C. Effects of lipoprotein(a) on success rate of thrombolytic therapy in acute myocardial infarction. Am J Cardiol 1991;67:1349-53.
18. Loscaizo J, Weinfeld M, Fless GM, Scanu AM. Lipoprotein(a), fibrin binding and plasminogen activation. Atherosclerosis 1990;10:241-5.
19. Karadi I, Kostner GM, Gries A, Nimph J, Romies L, Malle E. Lipoprotein(a) and plasminogen are immunochemicallly related. Biochem Biophys Acta 1988;960:91-7.
20. Falco C, Estelles A, Dalmau J, Espana F, Aznar J. Influence of lipoprotein(a) levels and isoforms on fibrinolitic activity-study in families with high lipoprotein(a) levels. Thromb Haemost 1998;79:818-23.
21. Jauhiainen M, Koskinen P, Ehnholm C, Frick MH, Manttari M, Manninen V et al. Lipoprotein(a) and coronary heart disease risk: a nested case-control study of the Helsinki Heart Study participants. Atherosclerosis 1991;89: 59-67.
22. Alfthan G, Pekkanen J, Jauhiainen M, Pitkaniemi J, Karvonen M, Tuomilehto J et al. Relation of serum homocysteine and lipoprotein(a) concentrations to atherosclerotic disease in a prospective Finnish population-based study. Atherosclerosis 1994;106:9-19.
23. Cremer P, Nagel D, Labrot B, Mann H, Muche R, Elster H et al. Lipoprotein(a) as predictor of myocardial infarction in comparison to fibrinogen, LDL cholesterol and other risk factors: results from the prospective Göttingen Risk Incidence and Prevelance Study (GRIPS). Eur J Clin Invest 1994;24:444-53.
24. Bostom AG, Cupples LA, Jenner JL, Ordovas JM, Seman LJ, Wilson PW et al. Elevated plasma lipoprotein(a) and coronary heart disease in men aged 55 years and younger: a prospective study. JAMA 1996;276:544-8.
25. Gavish D, Azrolan N, Breslow JL. Plasma Lp(a) concentration is inversely correlated with the ratio of Kringle IV/Kringle V encoding domains in the apo(a) gene. J Clin Invest 1989;184:2021-7.
26. Harpel PC, Gordon BR, Parker TS. Plasmin catalysis binding of lipoprotein(a) to immobilized fibrinogen and fibrin. Proc Natl Acad Sci U S A 1989;86:2374-7.
27. Hajjar KA, Gavish D, Breslow JL, Nachman RL. Lipoprotein(a) modulation of endothelial surface fibrinolysis and its potential role in atherosclerosis. Nature 1989;339: 303-5.
28. Miles LA, Fless CM, Levin EG, Scanu AM, Plow EF. A potential basis for the thrombotic risks associated with lipoprotein(a). Nature 1989;339:301-3.
29. Correc P, Kostner GM, Burtin P. A comparative study of the localisation of plasminogen and lipoprotein(a) in human carcinomas. Thromb Res 1990;58:213-20.
30. Moliterno DJ, Lange RA, Meidell RS, Willard JE, Leffert CC, Gerard RD et al. Relation of plasma lipoprotein(a) to infarct artery patency in survivors of myocardial infarction. Circulation 1993;88:935-40.
31. Heinrich J, Sandkamp M, Kokott R. Relation of Lp(a) to variables of coagulation and fibrinolysis in a healthy population. Clin Chem 1991;67:1349-59.